Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

6-MeO-DMT

Our opinion on this compoundNiche research probe

43/100

Useful SAR probe with a narrow research niche and almost no translational footing

Here’s the thing about 6-MeO-DMT: the most interesting fact about it is what it doesn’t do. It binds 5-HT2A, yes, but at 12- to 43-fold lower affinity than its 5-position cousin and roughly 6-fold below DMT. Put it in rodents and you get no head-twitch response, no substitution for DOM in drug discrimination, and no behavioral profile that looks psychedelic by any established metric. For a field trying to understand exactly which molecular features of the tryptamine scaffold drive hallucination, that negative result is actually information. That’s the case for keeping 6-MeO-DMT in the conversation at all.

The SAR story is real. Moving the methoxy group from position 5 to position 6 on the indole ring collapses serotonergic receptor affinity across multiple subtypes in ways that aren’t obviously predictable from the structure alone. 5-HT1A affinity drops roughly 110-fold relative to 5-MeO-DMT. That’s a striking position-sensitivity, and it gives researchers a tool to ask whether 5-HT2A agonism per se is sufficient for psychoplastogenic effects or whether there’s some receptor geometry or trafficking signature the low-affinity isomer misses. The emerging psychoplastogenesis-without-psychedelia research direction, led by groups like Bhatt and Bhatt and Olson’s lab at UC Davis, makes that question timely. Compounds like Tabernanthalog were designed precisely to probe it. 6-MeO-DMT gets there accidentally, by isomerism, which is both its appeal and its limitation.

The evidence problem is stark. The core literature is 1968 to the mid-1980s. Drug discrimination data exist; in vitro binding characterization is solid. But thats essentially the whole file. There is no human safety profile, no clinical experience, no replicated neuroplasticity work in vivo. The psychoplastogenic angle that makes this compound interesting in 2025 remains entirely extrapolated. We dont know if 6-MeO-DMT promotes dendritic growth the way Olson’s group showed with other low-affinity 5-HT2A agonists. We’re speculating in a direction that makes mechanistic sense, which is different from having data.

Against competitors, the picture tightens further. Tabernanthalog has more recent purpose-built evidence for non-hallucinogenic psychoplastogenesis. 6-Fluoro-DET occupies a similar structural-probe role. 6-MeO-DMT sits in a narrow band of utility: meaningful for labs doing serious tryptamine pharmacology or structure-activity dissection of the 5-HT2A activation complex, genuinely less useful for anyone chasing a translational signal. We think it belongs in the library as a reference and probe compound. We don’t think it belongs near the top of any sourcing priority list until someone actually characterizes its neuroplasticity profile in vivo. The bench value is real; the clinical relevance is speculative at best.

Novelty

50

Mechanism promise

62

In-category differentiation

45

Evidence quality

22

Translational signal

15

Research bench value

58

Rationale 6-MeO-DMT scores because its primary value is as a pharmacological dissection tool, not as a clinical candidate; attenuated 5-HT2A affinity and absence of hallucinogenic behavior in every animal model make it genuinely interesting for structure-activity work, but single-era preclinical evidence and zero human data cap both evidence and translational axes hard.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-hallucinogenic methoxytryptamine with attenuated serotonin receptor agonism at 5-HT2A and 5-HT1A subtypes

A 6-position methoxy-substituted N,N-dimethyltryptamine distinguished from its 5-methoxy positional isomer by dramatically reduced serotonin receptor affinity, absence of hallucinogenic activity in animal models, and emerging interest as a non-psychotomimetic tryptamine scaffold for structure-activity dissection and potential psychoplastogenic research.

Abstract

6-MeO-DMT (6-methoxy-N,N-dimethyltryptamine; CAS 2426-88-2) is a substituted indoleethylamine of the tryptamine structural class, defined by the placement of a methoxy substituent at the 6-position of the indole ring rather than at the 5-position occupied in its well-characterized positional isomer 5-MeO-DMT. The compound was first described in the scientific literature by 1968 and was assessed in structure-activity relationship studies of serotonergic tryptamines during the 1970s and 1980s. Despite acting as an agonist at the serotonin 5-HT2A receptor and as a non-selective agonist at multiple additional serotonin receptor subtypes, 6-MeO-DMT displays markedly reduced receptor affinity relative to both DMT and 5-MeO-DMT: its 5-HT2A binding affinity is 12- to 43-fold lower than that of 5-MeO-DMT and approximately 6-fold lower than that of DMT, while its 5-HT1A affinity is approximately 110-fold lower than that of 5-MeO-DMT. These attenuated binding properties correlate with the absence of the head-twitch response in rodent models, failure to substitute for the classical hallucinogen DOM in drug discrimination paradigms, and overall lack of psychedelic-like behavioral effects in all animal assays conducted to date.

The pharmacological profile of 6-MeO-DMT is of contemporary research interest for two principal reasons. First, the compound exemplifies how a single-atom positional shift of the methoxy group on the indole ring (from position 5 to position 6) produces a qualitative transition from hallucinogenic to non-hallucinogenic pharmacology while preserving the fundamental tryptamine scaffold and serotonin receptor agonist mechanism, providing a critical negative-control and structure-activity reference point for the investigation of 5-HT2A-mediated psychedelia. Second, the compound belongs to a growing class of non-hallucinogenic serotonin 5-HT2A receptor agonists (alongside tabernanthalog, 6-fluoro-DET, 2-bromo-LSD, lisuride, and others) that retain the capacity to promote neuroplasticity through 5-HT2A-dependent signaling without producing the subjective and behavioral effects associated with classical psychedelics, positioning it as a candidate scaffold for psychoplastogenic drug development.

6-MeO-DMT has not been tested in humans. No human pharmacokinetic, pharmacodynamic, or clinical efficacy data exist. The compound is presumed to undergo oxidative deamination by monoamine oxidase A (MAO-A) consistent with the metabolic fate of structurally related N,N-dimethylated tryptamines, with potential minor O-demethylation pathways contributing to total clearance. The compound is not an explicitly controlled substance in the United States, though it may be considered a Schedule I controlled substance as a positional isomer of 5-MeO-DMT under the Federal Analogue Act. This monograph reviews the chemistry, synthesis, and structural classification of 6-MeO-DMT; the receptor pharmacology and structure-activity relationships within the methoxytryptamine series; the extrapolated pharmacokinetic profile; the preclinical pharmacology evidence base; the absence of clinical data; sourcing and quality verification considerations; reconstitution and handling; stack interactions and combinations; adverse-event and safety signal assessment; and a comparative evaluation of five structurally or mechanistically related tryptamine compounds against 6-MeO-DMT on five assessment standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1594Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
BPN14770

Our opinion on this compoundNovel, promising

71/100

First-in-class allosteric PDE4D inhibitor that finally cracks the emesis problem haunting this target class

Look, the PDE4 space has a long and frustrating history. Rolipram was a promising research tool in the 1990s and then got killed in clinical development by nausea and vomiting at doses anywhere near therapeutically useful. Roflumilast eventually made it to market for COPD, but the emetic liability just pushed the therapeutic window too narrow to ever work in CNS indications. The field spent 25 years essentially stuck at that same problem. BPN14770 is the first serious answer to it.

What makes zatolmilast different isnt just subtype selectivity, thats been explored before with GEBR-7b and MK-0952. The genuinely new piece is the allosteric mechanism. Instead of competing at the PDE4D catalytic site the way rolipram does, BPN14770 binds the UCR2 helix in the N-terminal regulatory domain. That binding site is where the primate-specific story lives: there’s an amino acid residue in human PDE4D that confers roughly 100-fold greater potency than in rodent wild-type enzyme. Tetra demonstrated this elegantly with humanized transgenic mice, and that model predicts the therapeutic window accurately because the same primate-specific residue is absent in the receptor system driving emesis in non-human primate models. You end up with a projected 40- to 100-fold separation between cognitively active plasma exposures (10 to 30 ng/mL) and emesis-relevant exposures (around 1,300 ng/mL). That’s not incremental, thats a category-changing margin.

The mechanism downstream is well-understood: PDE4D inhibition elevates intracellular cAMP, which drives PKA, which phosphorylates CREB, which drives BDNF expression and synaptic plasticity. The LTP angle has been reproduced in multiple model systems. Whats compelling from a bench perspective is that BPN14770 lets you ask PDE4D-specific questions that rolipram never could. The 730-fold selectivity over PDE4B means you can dissect PDE4 subtype contributions to cAMP compartmentalization in neurons without the PDE4B-driven cardiovascular and inflammatory confounds that plague pan-PDE4 tools.

On the clinical side, the evidence base is real but still developing. The PICASSO trial in Alzheimer’s and the Fragile X crossover study both generated signals, and the ongoing EXPERIENCE phase 2b/3 program in Fragile X is the key readout to watch. Shionogi wouldnt have acquired Tetra in 2020 if the phase 2 data were ambiguous. The Jordan’s syndrome expansion adds another indication with meaningful unmet need and a mechanistically coherent rationale. We think the Fragile X program is the most interesting for bench researchers right now because it gives you a clean synaptic plasticity model with known genetic etiology and measurable endpoints.

What we dont love: the PDE4 class has enough clinical graveyard entries that we stay cautious on translational confidence until late phase 3 data exist. The preclinical signal in humanized mice is strong but also somewhat bespoke. And the cAMP-CREB pathway, while solid, is not exactly mysterious territory. Still, for researchers working on memory consolidation, neurodevelopmental biology, or cyclic nucleotide compartmentalization, BPN14770 is the most useful and most specific PDE4D tool that currently exists.

Novelty

70

Mechanism promise

78

In-category differentiation

78

Evidence quality

65

Translational signal

62

Research bench value

68

Rationale BPN14770 scores well on novelty and differentiation because the allosteric UCR2-helix binding mechanism and primate-specific potency enhancement are genuinely new pharmacology within a target class that has frustrated CNS researchers for three decades; evidence quality and translational signal are meaningful but not definitive, anchored by multiple phase 2 programs and an ongoing phase 2b/3 that hasnt yet read out.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-in-class allosteric inhibitor of phosphodiesterase-4D (PDE4D) with subtype selectivity and primate-specific potency enhancement

A PDE4D-selective allosteric inhibitor developed by Tetra Therapeutics (Shionogi) that enhances cAMP-PKA-CREB signaling to promote memory consolidation, synaptic plasticity, and neuroprotection, distinguished from classical PDE4 inhibitors by subtype selectivity and a wide therapeutic window separating cognitive benefit from emetic side effects.

Abstract

BPN14770 (zatolmilast) is a first-in-class, subtype-selective, allosteric inhibitor of phosphodiesterase-4D (PDE4D) that was discovered at Tetra Discovery Partners (later Tetra Therapeutics) and is currently in late-stage clinical development under Shionogi, which acquired Tetra in May 2020. The compound is distinguished from the two approved PDE4 inhibitors (roflumilast and apremilast) and from the classical PDE4 research tool rolipram by three principal features: allosteric rather than competitive inhibition of the PDE4D catalytic site, high selectivity for the PDE4D subtype over PDE4A, PDE4B, and PDE4C (approximately 730-fold selectivity over PDE4B), and exploitation of a primate-specific amino acid residue in the PDE4D N-terminal regulatory domain (UCR2 helix) that confers approximately 100-fold greater potency in humanized transgenic mice relative to wild-type mice, while simultaneously producing low potency in the xylazine/ketamine emesis surrogate assay. These properties yield a therapeutic index of 40- to 100-fold between plasma exposures that produce cognitive and neurochemical benefit (10 to 30 ng/mL) and those projected to cause emesis in non-rodent species (approximately 1,300 ng/mL), a margin that has historically been the dose-limiting constraint for PDE4 inhibitors in cognitive indications.

The molecular pharmacology of BPN14770 is centered on the cAMP-PKA-CREB signaling cascade. Inhibition of PDE4D elevates intracellular cyclic adenosine monophosphate (cAMP) in hippocampal and cortical neurons, activating protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB drives expression of brain-derived neurotrophic factor (BDNF), synapsin, postsynaptic density protein 95 (PSD-95), and other effectors of synaptic plasticity and memory consolidation. In humanized PDE4D mice, a single acute oral dose of BPN14770 at 0.01 mg/kg elevated hippocampal cAMP nearly threefold, augmented the late phase of long-term potentiation (LTP), reversed scopolamine-induced impairment of short-term memory, and improved long-term memory through a PKA-dependent mechanism confirmed by the PKA inhibitor H-89. Repeated dosing for 14 days at 0.03 mg/kg elevated hippocampal BDNF 2.1-fold and phospho-CREB 2.3-fold. In an amyloid-beta neurotoxicity model, 14-day oral BPN14770 at 0.01 to 0.03 mg/kg protected hippocampal pyramidal neurons from dendritic atrophy, preserved spine density, restored pCREB/CREB and BDNF/VGF ratios, and normalized spatial and working memory. A separate pathway analysis confirmed that BPN14770 engages the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling module, producing neuroprotective and anti-apoptotic effects.

Clinically, BPN14770 has been evaluated in two Phase 1 trials in 109 healthy adults (single doses up to 100 mg, multiple doses of 10 to 40 mg twice daily in elderly volunteers), a Phase 2 PICASSO trial in 255 patients with early Alzheimer’s disease (10 or 25 mg twice daily for 12 weeks), and a Phase 2 crossover trial in 30 adult males with Fragile X syndrome (25 mg twice daily for 12 weeks). The Phase 1 trials established linear pharmacokinetics, oral bioavailability of 70 to 80 percent, a plasma half-life of 8 to 10 hours, and a brain-to-plasma ratio of approximately 0.4. The PICASSO Alzheimer’s trial missed its primary endpoint (RBANS Delayed Memory Index) but showed a signal on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in a higher-dose subgroup. The Fragile X Phase 2 trial met its primary endpoint of safety and tolerability and demonstrated significant improvement on NIH Toolbox Oral Reading Recognition, Picture Vocabulary, and Cognition Crystallized Composite Score, with clinically significant caregiver-rated improvement in language and daily functioning. Shionogi subsequently initiated the EXPERIENCE Phase 2b/3 program comprising three studies (EXPERIENCE-204 in adolescents, EXPERIENCE-301 in adults, EXPERIENCE-302 open-label extension) for Fragile X syndrome. Topline results from the Phase 3 trials indicated that neither study met its originally specified primary endpoint of cognitive improvement on the NIH Toolbox, though the adult study (EXPERIENCE-301) showed statistically significant improvement on the caregiver-assessed Numeric Rating Scale. The compound holds FDA Fast Track designation, Orphan Drug designation in both the United States and European Union, and Rare Pediatric Disease designation for Jordan’s syndrome (Houge-Janssens syndrome 1), for which a Phase 2 trial enrolling 30 participants was initiated in February 2025.

The compound is well tolerated in clinical studies. The most common adverse events are headache, transient nausea, and vomiting, occurring at rates modestly above placebo. No serious adverse events attributable to the compound have been reported. The favorable emetic profile relative to classical PDE4 inhibitors reflects the allosteric mechanism and PDE4D subtype selectivity, which avoid the PDE4B-mediated emesis that limits rolipram and constrains roflumilast dosing.

This monograph reviews the chemistry, structural pharmacology, and primate-specific binding of BPN14770; the cAMP-PKA-CREB-BDNF signaling mechanism in molecular detail; the comprehensive preclinical pharmacology across scopolamine, amyloid-beta, and Fragile X models; human pharmacokinetics; the clinical evidence base in Alzheimer’s disease, Fragile X syndrome, and Jordan’s syndrome; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five PDE4 inhibitor candidates (roflumilast, apremilast, rolipram, MK-0952, GEBR-7b) against BPN14770 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1584Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
DNL343

Our opinion on this compoundNovel, promising

67/100

First-in-class eIF2B activator with real CNS PK and uncertain ALS clinical signal

Look, the eIF2B/ISR story is one of the more intellectually satisfying therapeutic hypotheses to emerge from basic neuroscience in the last decade. Peter Walter’s lab at UCSF essentially demonstrated that the integrated stress response, a pathway cells use to throttle down protein synthesis under duress, can be pharmacologically corrected in ways that rescue cognition and tissue function in animal models. ISRIB was the proof-of-concept molecule, and it worked beautifully in rodents. The problem was it couldn’t be developed into a real drug.

DNL343 is Denali’s answer to that problem. The central change is a bicyclo[1.1.1]pentane bioisostere in place of ISRIB’s central cyclohexane, and it genuinely matters: aqueous solubility improves, metabolic stability improves, and the compound achieves a brain-to-plasma unbound ratio of about 0.8 in rat with a 31-to-46-hour half-life in humans. That’s a compound you can actually run a chronic CNS trial with, and you couldn’t say that about ISRIB.

The mechanism is worth appreciating on its own terms. eIF2B is the guanine nucleotide exchange factor that recycles eIF2-GDP back to eIF2-GTP, required at every cycle of translation initiation. When the ISR fires, eIF2 gets phosphorylated and becomes an inhibitor of eIF2B, globally suppressing translation. DNL343 binds at the subunit interface of the eIF2B decamer and stabilizes the active conformation, essentially releasing the brake. In ALS, TDP-43 pathology activates ISR kinases, and the hypothesis is that chronic translational suppression contributes to progressive neuron loss. Its a real hypothesis with real preclinical support across TDP-43 proteinopathy and eIF2B loss-of-function models, both preventive and therapeutic paradigms.

What we like: the IC50 of 3.2 nM in the ATF4 reporter assay is genuinely potent, the Phase 1 safety profile is clean across dose cohorts, and once-daily oral dosing for a CNS compound with this level of brain penetration is harder to achieve than it sounds. The compound is also a more practical research tool than ISRIB for any lab that needs durable in vivo ISR suppression without IV delivery or solubility workarounds.

What we dont like: ALS is a brutal indication, and the HEALEY platform trial has a discouraging track record across most regimens. Phase 2/3 data for DNL343 is not encouraging, and effect sizes in neurodegeneration trials are persistently disappointing even when the underlying mechanism is sound. Theres also a real question about whether TDP-43 overexpression constructs, which anchor most of the preclinical case, faithfully capture human disease progression at the timescales relevant to a clinical trial.

Honestly, the compound’s most durable value may be as a pharmacological probe rather than a therapeutic. For groups working on ISR biology, TDP-43 pathology, or eIF2B complex structure and function, DNL343 is the most pharmaceutically competent in vivo tool currently available. That bench value stands regardless of what the ALS readout ultimately looks like.

Novelty

75

Mechanism promise

78

In-category differentiation

72

Evidence quality

58

Translational signal

40

Research bench value

68

Rationale DNL343 scores well on novelty and mechanism because the eIF2B/ISR axis is a genuinely new therapeutic target class with strong preclinical rationale; scores are pulled down by the ALS indication’s poor clinical track record and absent published Phase 2/3 efficacy, leaving translational signal low despite clean Phase 1 PK and a well-validated mechanism.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Small molecule eukaryotic initiation factor 2B (eIF2B) activator and integrated stress response (ISR) inhibitor

A potent, selective, CNS-penetrant bicyclo[1.1.1]pentane-centered eIF2B activator developed by Denali Therapeutics for the suppression of aberrant integrated stress response signaling in neurodegenerative disease, advanced through Phase 2/3 clinical evaluation in amyotrophic lateral sclerosis.

Abstract

DNL343 is a first-in-class, orally bioavailable, brain-penetrant small molecule activator of eukaryotic initiation factor 2B (eIF2B), the guanine nucleotide exchange factor that governs the rate-limiting step in translation initiation and serves as the principal regulatory node of the integrated stress response (ISR). The compound was designed at Denali Therapeutics as an improvement over the prototype tool compound ISRIB, which despite landmark demonstrations of cognitive enhancement and neuroprotection in rodent models suffered from poor aqueous solubility, limited oral bioavailability, and pharmaceutical intractability [1, 2]. DNL343 retains the symmetric bis-glycolamide pharmacophore that stabilizes the eIF2B decameric complex at the subunit interface but replaces the central cyclohexane of ISRIB with a bicyclo[1.1.1]pentane (BCP) bioisostere, conferring improved solubility, metabolic stability, and CNS penetration [3]. The compound displays an IC50 of 3.2 nanomolar in a cellular ATF4 reporter assay, a brain-to-plasma unbound concentration ratio of approximately 0.8 in rat, and a plasma elimination half-life of 31 to 46 hours in healthy human subjects, supporting once-daily oral dosing [3, 4, 5].

Preclinically, DNL343 produced dose-dependent neuroprotection in an optic nerve crush model of acute retinal ganglion cell degeneration and, in the Eif2b5 R191H knock-in mouse model of vanishing white matter disease (a genetic ISR-driven leukoencephalopathy), restored body weight, normalized motor function, reversed ISR transcriptional signatures, normalized plasma neurofilament light chain (NfL), and extended survival from 25 percent to 84.6 percent of treated animals when administered therapeutically at advanced disease stages [1]. In inducible TDP-43 proteinopathy mouse models relevant to amyotrophic lateral sclerosis (ALS), DNL343 attenuated ISR activation and reduced markers of neurodegeneration [6].

Clinical development proceeded through a Phase 1 trial in 95 healthy volunteers (single ascending doses of 15 to 800 mg; multiple ascending doses of 45 to 260 mg daily for 14 days), which demonstrated dose-proportional pharmacokinetics, cerebrospinal fluid (CSF) to unbound plasma ratios of 0.66 to 0.92, robust suppression of ISR biomarkers (ATF4 protein, CHAC1 transcript) in peripheral blood mononuclear cells, and a favorable tolerability profile with no serious adverse events [4, 5]. A Phase 1b study in 28 participants with ALS (100 and 200 mg daily for 28 days, followed by an 18-month open-label extension) confirmed CNS penetration with CSF-to-unbound-plasma ratios of 1.02 to 1.23, pharmacodynamic target engagement, and acceptable safety, with headache and fatigue as the most common treatment-emergent adverse events [7, 8]. The compound was subsequently advanced to Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, a 24-week randomized, placebo-controlled study enrolling 186 participants on DNL343 and 139 on placebo. In January 2025, Denali Therapeutics announced that the trial did not meet its primary endpoint of slowing disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival, and key secondary endpoints including muscle strength and respiratory function showed no statistical separation from placebo [9, 10]. A subsequent SEC filing revealed that DNL343 did not alter NfL biomarker levels over the treatment period [10]. The compound is no longer in active clinical development for ALS.

This monograph reviews the chemistry and design rationale of DNL343; the molecular pharmacology of eIF2B activation and ISR suppression; the comprehensive preclinical neuroprotection evidence; human pharmacokinetics across Phase 1 and Phase 1b studies; the clinical evidence base in ALS; sourcing, reconstitution, and handling considerations for research applications; stack interactions; the adverse-event profile; and a structured comparative assessment of five ISR-modulating agents (ISRIB, 2BAct, fosigotifator/ABBV-CLS-7262, IFB-088/Sephin1, and trazodone) against DNL343 on five competency standards. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers; investigators should confirm identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1574Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Omaveloxolone

Our opinion on this compoundEstablished, active research

63/100

Only approved therapy for Friedreich ataxia; clinically validated Nrf2 and NF-kB dual modulator with strong bench utility

Look, omaveloxolone earned its FDA approval the hard way: a rare disease, a small patient population, a mechanism that had to overcome years of skepticism about whether Nrf2 activation actually translated to clinical benefit in humans. The MOXIe Part 2 trial is a roughly 103-patient phase 2 RCT, not a massive phase 3 program, but in Friedreich ataxia that’s as good as it gets. When the agency approved Skyclarys in February 2023, it became the first and only pharmacotherapy in the indication. That’s not nothing.

The mechanism is what we like most here. Omaveloxolone works through covalent modification of Cys151 on KEAP1, the cytosolic repressor of Nrf2. Releasing Nrf2 drives a broad transcriptional program: HO-1, NQO1, glutathione synthesis enzymes, and mitochondrial biogenesis genes that are genuinely relevant to frataxin-deficiency pathology. The simultaneous NF-kB inhibition adds anti-inflammatory coverage without requiring a separate mechanism. It’s a dual-hit on oxidative stress and inflammation that makes biological sense in a disease driven by iron-sulfur cluster dysfunction and ROS accumulation.

Here’s where the score plateaus. The CDDO triterpenoid series is old chemistry. Bardoxolone methyl was in phase 3 trials a decade ago before the BEACON trial was halted due to cardiac events. Omaveloxolone is clearly the better-engineered analog, and the therapeutic index at 150 mg/day oral appears genuinely improved, but the compound class isn’t fresh to the research conversation. Investigators who’ve been watching this space have been watching it for years. The novelty score reflects that.

Evidence quality is real but constrained by the indication. MOXIe Part 2 showed a statistically significant improvement on mFARS versus placebo, and extension cohort data suggest durability of effect. For a disease with no prior approved therapy thats compelling. For a researcher expecting gold-standard evidence, it’s one pivotal phase 2 trial in roughly 100 patients, not yet independently replicated by a second RCT from a separate group.

For bench scientists, the research utility is solid. Omaveloxolone is the most potent and clinically validated KEAP1-Nrf2 axis modulator available at research scale. If you’re studying Nrf2 biology, mitochondrial cytoprotection in neurodegeneration models, or FA pathophysiology directly, this is a genuinely useful probe. its superior therapeutic index versus bardoxolone makes it a more tractable tool in experimental contexts. The oncology and radiation dermatitis programs are interesting side stories: phase 1/2 data suggest Nrf2-driven cytoprotection is actionable in cancer treatment settings, though those arms haven’t produced late-stage confirmation yet. All of that adds up to a strong niche compound with real clinical grounding, placed appropriately in the established-active tier.

Novelty

50

Mechanism promise

65

In-category differentiation

68

Evidence quality

68

Translational signal

70

Research bench value

60

Rationale Omaveloxolone scores well on differentiation and translational signal as the first FDA-approved FA therapy with a real phase 2 RCT behind it, but novelty is moderated by its origins in the decades-old CDDO triterpenoid series; the 63 overall reflects a well-validated niche compound rather than a frontier discovery.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Semi-synthetic oleanane triterpenoid Nrf2 activator and NF-kappaB inhibitor

A second-generation synthetic triterpenoid developed by Reata Pharmaceuticals as a potent activator of the Nrf2 cytoprotective pathway and the first FDA-approved pharmacotherapy for Friedreich ataxia, distinguished from earlier Nrf2 modulators by clinical validation in a neurodegenerative indication and a favorable therapeutic index at the registered oral dose.

Abstract

Omaveloxolone (RTA 408; marketed as Skyclarys) is a semi-synthetic oleanane triterpenoid and potent activator of nuclear factor erythroid 2-related factor 2 (Nrf2) that received United States Food and Drug Administration approval in February 2023 as the first and, as of the date of this monograph, only pharmacotherapy indicated for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older. The compound operates through a dual mechanism: covalent modification of sensor cysteines (primarily Cys151) on the Kelch-like ECH-associated protein 1 (KEAP1) repressor, which stabilizes Nrf2 and permits its nuclear translocation and transcriptional activation of antioxidant response element (ARE)-driven cytoprotective genes; and direct inhibition of the nuclear factor kappaB (NF-kappaB) pro-inflammatory signaling cascade. These combined activities restore mitochondrial bioenergetics, elevate intracellular glutathione, induce heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1), and suppress inflammatory cytokine production in both cellular and animal models of oxidative stress and neurodegeneration.

The clinical development of omaveloxolone centered on the MOXIe program (NCT02255435), a two-part, randomized, double-blind, placebo-controlled trial conducted across 11 institutions in the United States, Europe, and Australia. In MOXIe Part 2, 103 patients with genetically confirmed Friedreich ataxia aged 16 to 40 years were randomized 1:1 to placebo or omaveloxolone 150 mg orally once daily for 48 weeks. The primary endpoint, change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS), demonstrated a statistically significant placebo-corrected difference of negative 2.40 points (p = 0.014), with omaveloxolone-treated patients showing neurological improvement (negative 1.55 points) against placebo-treated worsening (positive 0.85 points). Extension data and propensity-matched natural history comparisons have supported persistent benefit over four years of continuous treatment.

Pharmacokinetics are characterized by slow and variable oral absorption (median time to peak concentration 7 to 14 hours), high protein binding (97 percent), a large apparent volume of distribution (approximately 7361 liters), and a long terminal elimination half-life (mean 57 hours, range 32 to 90 hours). Metabolism is predominantly hepatic via cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP2C8 and CYP2J2. Elimination is primarily through the hepatobiliary route and fecal excretion. A clinically significant food effect is present: coadministration with a high-fat meal increases peak plasma concentration (Cmax) by approximately 350 percent with only a 15 percent increase in total exposure (AUC), necessitating fasted-state administration. Strong CYP3A4 inhibitors increase omaveloxolone exposure approximately 4-fold and require dose modification.

The principal adverse events in clinical trials were elevated hepatic aminotransferases (alanine aminotransferase elevation in 37 percent of patients, with 16 percent exceeding 5 times the upper limit of normal), headache, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain. The aminotransferase elevations have been attributed to enzyme induction rather than hepatocellular injury, as bilirubin and albumin levels remained within normal limits; however, periodic hepatic function monitoring is required during treatment. Earlier clinical programs explored omaveloxolone in oncology (advanced solid tumors, melanoma adjunct to checkpoint inhibitors) and radiation dermatitis (topical formulation), though the Friedreich ataxia indication is the sole approved application.

This monograph documents the chemistry, synthesis, and structural class of omaveloxolone; the molecular pharmacology of the KEAP1-Nrf2-ARE axis and NF-kappaB inhibition; comprehensive pharmacokinetics including food effect, drug interactions, and special populations; the preclinical pharmacology across oxidative stress and mitochondrial dysfunction models; the clinical evidence base from the MOXIe program and oncology studies; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse event and safety profile; and a structured comparative assessment of five alternative Nrf2-modulating or Friedreich ataxia-relevant compounds (dimethyl fumarate, sulforaphane, bardoxolone methyl, idebenone, EPI-743) against omaveloxolone on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1606Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
5-MeO-DALT

Our opinion on this compoundNiche research probe

42/100

A distinctive polypharmacological probe with a well-characterized receptor fingerprint but near-zero translational data

The Klein and Cozzi receptor panel from 2018 is the reason 5-MeO-DALT is worth knowing about at all. Forty-five cloned human receptors, nanomolar affinity at 5-HT1A (Ki roughly 19 nM), meaningful hits at 5-HT2B, 5-HT7, sigma-1, sigma-2, kappa-opioid, and alpha-2A adrenergic. That is not the fingerprint of a standard tryptamine psychedelic. Most 5-MeO compounds are relatively clean 5-HT1A/2A tools. The N,N-diallyl substitution produces a genuinely broader polypharmacological profile, and for a group trying to understand how receptor polypharmacology shapes tryptamine phenomenology, this is a legible and differentiated probe with a defined identity.

The sigma and kappa angles are what we find most interesting. Sigma-1 modulation intersects neuroprotection research and psychoplastogen biology; kappa-opioid activity sitting alongside 5-HT2A creates real opportunities for dissecting dissociative versus classical serotonergic psychedelic effects in the same compound. That cross-receptor combination doesnt come packaged this neatly in many available tools. Short duration (2 to 4 hours per Michely et al. 2015) is also a practical plus for study design when behavioral readouts are involved.

Beyond receptor profiling, though, the evidence base is thin. The Michely metabolism work is solid in vitro and rat data, but isnt safety pharmacology. The clinical picture is entirely case reports documenting intoxication, including rhabdomyolysis and one fatality. No formal studies, no replicated behavioral data beyond mouse head-twitch response (ED50 2.25 mg/kg), no genotoxicity, no repeated-dose characterization. What we have is a well-mapped binding profile with essentially nothing validated downstream of it.

Translational signal is close to zero for any useful endpoint. Anecdotal cluster headache reports circulate in the NPS literature, but nothing approaching phase 0 data exists. The preclinical safety space is genuinely unmapped, which limits what any conscientious program can do with it regardless of interest in the mechanism. Legal status adds friction without being a hard federal barrier for US investigators as of this writing, but UK Class A status and state-level scheduling in Florida and Louisiana narrow the accessible research community significantly.

This is a secondary-probe compound at best. Its place is inside a polypharmacology program already working on the sigma or kappa-opioid/serotonin interface, where the distinctive receptor fingerprint adds something established tools don’t cover. For anyone outside that narrow use case, the absence of translational signal and the preclinical data gap make it easy to deprioritize in favor of compounds with cleaner paths and more complete evidence packages.

Novelty

45

Mechanism promise

58

In-category differentiation

42

Evidence quality

33

Translational signal

22

Research bench value

48

Rationale Scored primarily on the strength of the Klein, Cozzi, Daley, Brandt, and Halberstadt 2018 receptor panel, which is real and differentiated work establishing a genuinely unusual sigma/KOR/serotonin polypharmacological profile, but the compound has no clinical studies, no safety pharmacology, and no translational signal for any useful endpoint, placing it at the low end of niche-probe territory with negligible path forward.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic N,N-diallyltryptamine psychedelic with polypharmacological serotonin, sigma, and kappa-opioid receptor activity

A synthetic 5-methoxy-substituted N,N-diallyltryptamine first disclosed by Alexander Shulgin in 2004, distinguished from classical tryptamine psychedelics by broad-spectrum receptor polypharmacology spanning serotonergic, sigma, adrenergic, and kappa-opioid targets, and characterized in recent receptor binding and behavioral pharmacology studies as a 5-HT2A partial agonist with rapid onset and short duration of action.

Abstract

5-MeO-DALT (N,N-diallyl-5-methoxytryptamine; CAS 928822-98-4) is a synthetic substituted tryptamine first synthesized and disclosed by Alexander Shulgin in May 2004 and subsequently disseminated through online research chemical markets. The compound is a structural analog of N,N-diallyltryptamine (DALT) bearing a 5-methoxy substituent on the indole ring, placing it in the broader family of 5-methoxy-substituted tryptamines alongside 5-MeO-DMT, 5-MeO-DiPT, and 5-MeO-MiPT, while the N,N-diallyl substitution pattern distinguishes it from all clinically investigated members of this series. Receptor binding profiling conducted by Cozzi and Daley (2016) and extended by Klein, Cozzi, Daley, Brandt, and Halberstadt (2018) across panels of 45 cloned human receptors and transporters has established that 5-MeO-DALT exhibits nanomolar affinity at the 5-HT1A receptor (Ki approximately 19 nM), the 5-HT2B receptor (Ki approximately 59 nM), the 5-HT7 receptor (Ki approximately 90 nM), and the 5-HT1D receptor (Ki approximately 107 nM), with additional sub-micromolar binding at the 5-HT6, 5-HT2A, alpha-2A adrenergic, sigma-1, and sigma-2 receptors. Functional assays demonstrate full agonist activity at the 5-HT1A receptor (Emax 99 to 102 percent of reference) and partial to full agonist activity at the 5-HT2A receptor (Emax 91 to 114 percent), the latter consistent with the hallucinogenic behavioral profile observed in the mouse head-twitch response assay (ED50 2.25 mg/kg). The compound additionally exhibits measurable affinity at the kappa-opioid receptor and weak activity at dopamine and serotonin transporters, producing a polypharmacological fingerprint that is broader than that of classical N,N-dimethyltryptamine analogs and that may account for the subjective profile described in self-experimentation reports as qualitatively distinct from other 5-methoxytryptamines. Pharmacokinetic characterization is limited to forensic and case-report data. Oral onset is rapid (less than 15 minutes), duration is short (2 to 4 hours), and the metabolic disposition involves CYP1A2, CYP2C19, CYP2D6, and CYP3A4-mediated N-dealkylation, hydroxylation (both aromatic and aliphatic), O-demethylation, and glucuronide conjugation, as characterized in the Michely et al. (2015) in vitro and rat in vivo metabolism study. A clinical case report documented a serum concentration of 7 ng/mL at 8 hours after ingestion of approximately 97.5 mg, with complete clinical recovery by 12 hours, consistent with a short elimination half-life. The compound has no therapeutic indication, no approved clinical use, and no registration in any jurisdiction. It is classified as a novel psychoactive substance and is controlled in Japan (2007), Sweden (2012), the United Kingdom (2015, Class A), China (2015), Singapore (2015), and in the United States states of Florida and Louisiana (Schedule I), but is not scheduled at the United States federal level. The published toxicological literature comprises a small number of case reports documenting loss of consciousness, visual hallucinations, delirium, rhabdomyolysis, and one reported fatality. No systematic preclinical safety pharmacology, reproductive toxicology, or genotoxicity studies have been published. This monograph documents the chemistry, synthesis, receptor pharmacology, metabolism, behavioral pharmacology, reported adverse events, legal status, and comparative positioning of 5-MeO-DALT against five structurally or pharmacologically related tryptamines across five assessment standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1595Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Ariadne

Our opinion on this compoundNiche research probe

55/100

Rare non-hallucinogenic 5-HT2A agonist with inaccessible Phase II data and real probe value for dissecting hallucinogenesis mechanisms

Look, Ariadne is one of those compounds that forces you to sit with a frustrating historical accident. Shulgin synthesized it in 1968 as the alpha-ethyl homolog of DOM, and what he found was a potent 5-HT2A agonist that apparently doesn’t hallucinate people. Bristol-Myers ran Phase II trials in the early 1970s under development code BL-3912A (the preferred R-enantiomer) in schizophrenia, Parkinson’s, and geriatric cognition. Reported results were striking: rapid psychotic symptom remission, near-complete motor reversal in Parkinson’s at 100 mg daily, no hallucinogenic effects even above 300 mg. Then Bristol-Myers stopped for economic reasons and never published the data. Thats where things stand, fifty years later.

The mechanism is what makes it genuinely interesting as a research tool. The working hypothesis is that the alpha-ethyl extension reduces intrinsic signaling efficacy at 5-HT2A without abolishing receptor binding, and that reduced efficacy is what dissociates the hallucinogenic from the therapeutic signal. This connects to live debates about which downstream pathway (IP3 cascade, beta-arrestin, or something else) actually drives hallucinogenesis. Structurally, Ariadne is a minimal probe: same scaffold as DOM, one extra carbon, radically different behavioral profile. You can compare it directly against DOM and DOI with a single structural variable. That’s clean SAR work.

The contemporary context adds relevance. The non-hallucinogenic psychoplastogen space is active right now: DLX-001 (AAZ-A-154), tabernanthalog (TBG), lisuride. Most of that work sits in tryptamine scaffolds. Ariadne is a phenylalkylamine and predates all of it by fifty years. For labs trying to map the structural determinants of hallucinogenesis across chemotypes, Ariadne isn’t redundant with the tryptamine-based probes. That’s distinct bench value.

What we don’t like: the evidence situation is bad in a very specific way. The Bristol-Myers clinical data has never been publicly disclosed, meaning the most compelling efficacy claims are unverifiable secondhand accounts. The published base is thin: mouse PK data, a NIDA characterization study, Shulgin self-reports, scattered online accounts. You cant build a rigorous program on that without the underlying clinical package. The compound also occupies uncomfortable legal territory given structural proximity to Schedule I DOM, which creates real sourcing friction even for legitimate labs.

Honestly, Ariadne scores as a niche probe rather than a development candidate. Its value is mechanistic: as a tool for dissecting the hallucinogenesis-versus-therapeutic-signal question at 5-HT2A in a non-tryptamine scaffold, its one of the cleaner instruments available. But the inaccessible clinical history, thin published preclinical base, and legal ambiguity all limit what a research program can practically do with it right now, and the score reflects that tension.

Novelty

58

Mechanism promise

72

In-category differentiation

55

Evidence quality

30

Translational signal

40

Research bench value

70

Rationale Ariadne scores primarily on mechanism promise and bench value as a structurally minimal probe for the hallucinogenesis-versus-therapeutic-signal question at 5-HT2A; evidence quality is severely limited by the never-disclosed Bristol-Myers clinical package, anchoring the overall despite genuine contemporary relevance in the non-hallucinogenic psychoplastogen space.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-hallucinogenic 5-HT2A receptor agonist of the substituted phenylalkylamine (phenylisobutylamine) class

A non-hallucinogenic serotonin 5-HT2A receptor agonist of the substituted phenylalkylamine class, distinguished from hallucinogenic congeners DOM and DOI by a single alpha-ethyl extension that attenuates signaling efficacy while preserving therapeutic activity across psychiatric, neurological, and movement disorder indications.

Abstract

Ariadne (4C-D; BL-3912; dimoxamine), the alpha-ethyl homolog of the hallucinogenic amphetamine DOM, is a potent and selective agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors that is distinguished by a striking dissociation between receptor activation and hallucinogenic effect in humans. First synthesized by Alexander Shulgin in 1968 and advanced through Phase II clinical trials at Bristol-Myers Laboratories in the early 1970s under the development code BL-3912A (the pharmacologically preferred R-enantiomer), the compound produced rapid remission of psychotic symptoms in schizophrenia and bipolar patients at 50 to 100 mg per day, nearly complete reversal of motor deficits in Parkinson’s disease patients at 100 mg per day, and improved cognitive alertness in geriatric subjects at 50 mg per day, all without hallucinogenic effects at doses up to and beyond 300 mg. Development was halted for strategic economic reasons rather than for safety or efficacy concerns, and the actual clinical data from the Bristol-Myers trials were never publicly disclosed.

The molecular pharmacology of Ariadne was formally characterized by the Cunningham, Sames, and McCorvy laboratories at Columbia University in a 2022 publication in ACS Chemical Neuroscience. The R-enantiomer binds the human 5-HT2A receptor with a Ki of 53 nM (radioligand displacement against [125I]-DOI), activates Gq-coupled signaling with an EC50 of 149 nM and an Emax of 83 percent relative to serotonin, and produces calcium flux with an EC50 of 30 nM and an Emax of 96 percent. The compound shows no substantial bias between Gq/11 and beta-arrestin2 signaling pathways. Instead, the non-hallucinogenic profile is attributed to a consistent 4- to 6-fold reduction in potency and a 10 to 20 percent reduction in maximal efficacy across all measured signaling channels relative to the hallucinogenic reference compound DOM. This “signaling efficacy hypothesis” proposes that the lower overall transduction amplitude, rather than pathway-selective biased agonism, accounts for the preservation of therapeutic effects in the absence of hallucination.

Selectivity profiling across a 44-target safety panel identified only the 5-HT2A and 5-HT2B receptors as targets displaced above 50 percent at 10 micromolar concentration. The compound has no measurable activity at dopamine, norepinephrine, or serotonin transporters (IC50 values exceeding 50 micromolar), no activity at dopamine D1 or D2 receptors, and weak submicromolar activity at 5-HT1A, 5-HT1D, 5-HT1E, and 5-HT1F receptors. In mice, subcutaneous administration at 10 mg/kg produces peak plasma concentrations of approximately 467 ng/mL at 15 minutes, a brain-to-plasma ratio of 10.23 at 1 hour, and a plasma elimination half-life of approximately 2.1 hours, confirming high central nervous system penetration.

Preclinical studies in auxilin-knockout mice (a genetic model of Parkinson’s disease) demonstrated that a single 10 mg/kg dose of (R)-Ariadne restored balance beam performance to wildtype levels and eliminated hind limb clasping scores, mirroring the effects of levodopa despite the compound’s lack of dopaminergic receptor or transporter activity. In the novelty-suppressed feeding test, a sustained anxiolytic-like effect was observed 7 days after a single administration, consistent with the neuroplasticity-dependent mechanisms proposed for 5-HT2A agonist therapeutic effects. A 2024 patent application by Columbia University (WO2024073601A2) claims therapeutic applications across movement disorders, neuropsychiatric conditions, cognitive impairment, substance use disorders, and catatonia. This monograph reviews the chemistry, stereochemistry, and synthesis of Ariadne; the receptor pharmacology and signaling mechanism in molecular detail; available pharmacokinetic data; the historical clinical evidence from Bristol-Myers and the contemporary preclinical pharmacology from the Sames laboratory; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a structured comparative assessment of five non-hallucinogenic 5-HT2A receptor agonists against Ariadne on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1572Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Citrus-Bergamot

Our opinion on this compoundEstablished, active research

44/100

Pleiotropic lipid-lowering botanical with unique HMG-flavanone chemistry, outcompeted in the metabolic AMPK space by berberine

Look, the most interesting thing about bergamot polyphenolic fraction isnt the lipid-lowering headline, its the chemistry. Brutieridin and melitidin are structurally analogous to the HMG-CoA substrate of HMGCR, which means they interact with cholesterol biosynthesis machinery in a way that is mechanistically distinct from competitive statin inhibition. Thats a genuine insight. The BPF package also layers in AMPK phosphorylation, NPC1L1 downregulation at the gut epithelium, and anti-inflammatory signaling through multiple polyphenol-class mechanisms. Multi-target, pleiotropic, and not simply statin-lite.

Here’s the thing though: AMPK activation as a strategy for metabolic syndrome has been very heavily mined. Berberine activates AMPK, has a more defined single-molecule profile, and carries a deeper and more geographically diverse clinical literature. BPF competes in a space that berberine currently owns, and berberine wins most head-to-head comparisons on evidence density. We like the bergamot chemistry story, but when you’re allocating bench time to lipid and metabolic research, berberine is the cleaner probe and the stronger comparator. Differentiation relative to berberine is real but not dominant.

The clinical evidence for BPF is real. Multiple trials show meaningful LDL reduction, triglyceride lowering, and modest glycemic improvement across dyslipidemia and metabolic syndrome populations. The NAFLD signals are interesting early work. What we dont like is that much of the published literature involves commercial extract sponsorship, most trials are modest-N single-center designs, and independent group replication is thinner than you’d want. It’s better than single-lab-only status, but it’s not at the level where you cite a dozen independent confirmations from groups with no extract stake.

The antipsychotic-associated metabolic dysfunction angle is honestly the most differentiated niche here. Second-generation antipsychotics drive metabolic disruption through mechanisms that don’t fully overlap with standard dyslipidemia pathways, and BPF has been specifically studied in that population. Berberine doesn’t occupy that niche as clearly. For a research program focused on iatrogenic metabolic dysregulation, bergamot earns real attention that most botanicals wouldn’t.

As a bench probe its complexity is a limitation. BPF is a multi-component mixture with meaningful batch-to-batch variability across Bergavit, Bergamonte, and BergaMet preparations, each standardized to different flavonoid targets. That makes clean mechanistic conclusions harder to draw. Studying brutieridin or melitidin as isolated compounds would be more interesting bench chemistry than working with the whole fraction, and we’d like to see more of that in the literature. Until it exists, working with BPF requires careful sourcing discipline and tolerance for mechanistic ambiguity.

Novelty

35

Mechanism promise

50

In-category differentiation

42

Evidence quality

48

Translational signal

50

Research bench value

35

Rationale The standardized BPF extract is rated on its own merits rather than as a generic food botanical: the HMG-conjugated flavanones brutieridin and melitidin represent a mechanistically distinct entry point into cholesterol biosynthesis regulation, and the multi-target profile (HMGCR transcriptional, AMPK, NPC1L1) is genuinely interesting. Scores are held down by competition from berberine on most metabolic endpoints, modest-N commercially-linked clinical literature, and the inherent noise of working with a complex botanical mixture.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Polyphenol-rich Citrus flavonoid extract with AMPK-activating, hypolipidemic, and insulin-sensitizing activity

A standardized polyphenolic extract derived from Citrus bergamia Risso & Poiteau, distinguished by the presence of the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanones brutieridin and melitidin, and investigated for cardiovascular risk factor modification through pleiotropic lipid-lowering, glycemic, hepatoprotective, and anti-inflammatory mechanisms.

Abstract

Citrus bergamot extract, derived from the juice and albedo of the bergamot orange (Citrus bergamia Risso & Poiteau), is a polyphenol-rich botanical preparation whose pharmacological interest centers on a distinctive flavonoid profile that includes the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanone glycosides brutieridin and melitidin, alongside high concentrations of neoeriocitrin, naringin, and neohesperidin. These HMG-bearing flavanones are structurally analogous to the HMG-CoA substrate of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis and the molecular target of statin drugs. In vitro mechanistic studies in HepG2 and Caco-2 cell lines have demonstrated that bergamot polyphenolic fraction (BPF) and its principal constituents reduce HMGCR protein levels, activate AMP-activated protein kinase (AMPK) phosphorylation, stimulate fatty acid oxidation, and inhibit intestinal cholesterol absorption through downregulation of the Niemann-Pick C1-Like 1 (NPC1L1) transporter. The mechanism is therefore distinct from direct competitive HMGCR inhibition by statins and involves transcriptional and post-translational regulation of cholesterol biosynthetic and absorptive pathways.

Clinical investigation of bergamot polyphenolic extracts has been conducted primarily in Southern Italian populations with hyperlipidemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). In the pivotal Mollace et al. (2011) open-label study of 237 patients with moderate hypercholesterolemia, BPF at 500 mg or 1000 mg daily for 30 days reduced total cholesterol by 22 to 31 percent, low-density lipoprotein cholesterol (LDL-C) by 24 to 36 percent, and triglycerides by 28 to 41 percent, while increasing high-density lipoprotein cholesterol (HDL-C) by 22 to 40 percent. Subsequent randomized, double-blind, placebo-controlled trials have confirmed statistically significant reductions in LDL-C and triglycerides at doses of 500 to 1300 mg daily over 6 to 24 weeks, with concurrent improvements in fasting glucose, HOMA-IR insulin resistance index, and hepatic steatosis markers. A 2020 randomized trial of a bergamot-cardoon combination (Bergacyn) in NAFLD patients over 50 years demonstrated significant reductions in liver steatosis, body weight, and hepatic transaminases.

The pharmacokinetic profile of bergamot flavonoids in humans is incompletely characterized. Oral consumption produces circulating phase II conjugated metabolites (sulfates and glucuronides of naringenin, hesperetin, and eriodictyol) detectable at 1 and 4 hours post-ingestion, consistent with intestinal deglycosylation and hepatic phase II conjugation. The characteristic HMG-conjugated flavanones brutieridin and melitidin have not been detected in plasma or urine in published pharmacokinetic studies, raising the possibility that their hypolipidemic activity is mediated locally in the gastrointestinal epithelium or through metabolites not yet characterized. The extract is generally well tolerated in clinical studies of up to 24 weeks duration, with adverse events limited to mild gastrointestinal discomfort in a minority of subjects. Bergamot contains furanocoumarins (bergamottin, bergapten) that inhibit CYP3A4, producing clinically relevant interactions with statins metabolized by this isoform (atorvastatin, simvastatin, lovastatin) and other CYP3A4 substrates. This monograph reviews the botanical identification, phytochemistry, and standardization of bergamot extract; the molecular pharmacology of its principal flavonoid constituents; the pharmacokinetic record; the preclinical and clinical evidence base across dyslipidemia, metabolic syndrome, NAFLD, and glycemic endpoints; sourcing and quality verification; handling considerations; stack interactions; adverse-event signal; and a comparative assessment of five alternative lipid-modifying nutraceuticals (red yeast rice, berberine, plant sterols/stanols, niacin, and artichoke leaf extract) against citrus bergamot on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1561Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Itruvone

Our opinion on this compoundNovel, promising

60/100

Genuinely novel non-systemic antidepressant pherine with early clinical signal and unique nasal-limbic circuit mechanism

Look, the pherine concept has been sitting in the periphery of neuropsychiatry for over two decades, and itruvone is the most clinically advanced member of that class targeting depression. The core idea is genuinely strange in the best possible way: deliver a synthetic pregnane steroid to the nasal epithelium at microgram-level doses (3.2 to 6.4 micrograms per intranasal spray), activate chemosensory receptor neurons in the nasal mucosa, and drive a neurochemical cascade through olfactory bulb projections into the amygdala and hypothalamus that ultimately increases catecholamine release from midbrain nuclei. No systemic absorption required. No BBB crossing. No receptor occupancy in the traditional CNS pharmacology sense. Thats a fundamentally different architecture than anything approved for MDD.

The mechanistic logic tracks. The olfactory-amygdala-hypothalamic axis has real anatomical substrate: olfactory sensory neurons project directly to the amygdala via the olfactory tract without a thalamic relay, which is part of why smells have such immediate emotional salience. Using that circuit as a pharmacological inlet for psychiatric modulation isn’t crazy; it’s just never been reduced to practice at clinical scale before. Itruvone’s sister compound fasedienol (PH94B, Aloradine) is advancing through the same platform for social anxiety disorder and has cleaner clinical data behind it. That parallel development matters, because it validates the pherine mechanism class across indications rather than a single idiosyncratic effect.

What we like: the differentiation story is real. You cannot compare this to an SSRI, a GABA modulator like brexanolone or zuranolone, or to esketamine. The mechanism is orthogonal. For investigators studying non-systemic CNS access routes, olfactory-limbic circuit pharmacology, or looking for a tool to probe catecholaminergic modulation without the confounds of systemic drug exposure, itruvone has genuine probe value you cant replicate with anything else currently in the toolkit.

What we dont love: the evidence base is thin by any serious standard. The primary MDD clinical signal comes from a Phase 2A trial conducted in Mexico, small N, not yet replicated by an independent group. The U.S. Phase 1 was a safety and tolerability study only, not an efficacy read. The mechanistic story at the receptor level is proposed and supported by in vitro chemosensory electrophysiology and behavioral pharmacology, but the full circuit pathway in humans remains incompletely characterized. We’d want independent Phase 2B data and cleaner mechanistic confirmation before calling this anything more than a promising early signal.

Honestly, the score here is bounded by evidence, not by concept. The concept deserves more credit than the current data can support. Serious investigators building nasal-to-brain pharmacology programs or studying olfactory-limbic circuit modulation should have this on their radar now. General neuropharmacology programs can afford to wait for the next trial readout.

Novelty

65

Mechanism promise

75

In-category differentiation

70

Evidence quality

38

Translational signal

45

Research bench value

58

Rationale Itruvone scores on strong mechanistic differentiation (non-systemic nasal chemosensory route, orthogonal to all approved antidepressants) but is bounded by a thin single-trial clinical evidence base and a mechanistic model that remains incompletely characterized in humans.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic pregnane neuroactive steroid vomeropherine acting via nasal chemosensory receptor activation of olfactory-amygdala neural circuits

A synthetic pregnane steroid pherine developed by Pherin Pharmaceuticals and advanced by VistaGen Therapeutics as an intranasal microgram-dose nasal spray for major depressive disorder, distinguished from all approved antidepressants by a proposed non-systemic mechanism of action operating through peripheral nasal chemosensory neuron activation of limbic-hypothalamic catecholaminergic circuits without requirement for blood-brain barrier penetration or direct central nervous system receptor engagement.

Abstract

Itruvone (PH10; pregn-4-en-20-yn-3-one; CAS 21321-89-1) is a synthetic neuroactive steroid of the pregnane class and the second clinical-stage pherine (vomeropherine) molecule, under development by VistaGen Therapeutics as an intranasal nasal spray for the treatment of major depressive disorder (MDD). The compound is structurally characterized by a 17-alpha-ethynyl substituent on the pregnane steroid nucleus and a 3-keto-4-ene A-ring motif, yielding an odorless crystalline material with a molecular weight of 296.45 g/mol and the molecular formula C21H28O. Itruvone is pharmacologically distinguished from all currently approved antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and the rapid-onset agents esketamine and brexanolone, by a proposed mechanism of action that does not require systemic absorption or direct activity on neuronal receptors in the brain. Instead, the compound is administered at microgram-level intranasal doses (3.2 to 6.4 micrograms per day) and is designed to engage and activate chemosensory receptor neurons in the nasal epithelium, which in turn activate olfactory bulb projections to the amygdala, hypothalamus, and prefrontal cortex through olfactory-amygdala neural circuits believed to modulate the activity of the limbic-hypothalamic sympathetic nervous system and increase the release of catecholamines from midbrain nuclei.

Preclinical tissue distribution studies using radiolabeled [14C]PH10 in rats demonstrated that a single intranasal administration was essentially undetectable in the brain and most other tissues, including blood and plasma, supporting the hypothesis that therapeutic activity occurs through peripheral chemosensory signaling rather than through systemic drug exposure. Preclinical electrophysiology studies further demonstrated that itruvone’s mechanism does not involve direct activation of GABA-A receptors in the brain, differentiating it from benzodiazepines and from the neurosteroid antidepressant brexanolone (allopregnanolone).

The clinical evidence base comprises a positive Phase 2A randomized, double-blind, placebo-controlled trial conducted in Mexico in 30 patients with MDD, in which daily self-administered intranasal itruvone at 6.4 micrograms produced a mean 17-item Hamilton Depression Rating Scale (HAM-D-17) score reduction of 10.1 points after one week (compared to 4.2 points for placebo, p = 0.03) and 17.8 points after eight weeks, with the drug well tolerated and minimal side effects reported; a successful U.S. Phase 1 safety and tolerability study in healthy adult subjects completed in 2023 with no serious adverse events, no discontinuations due to adverse events, and only two mild adverse events (fatigue and headache in the same subject); and supportive prior clinical studies. The U.S. Food and Drug Administration has granted Fast Track designation for the development of itruvone as a potential treatment for MDD.

This monograph reviews the chemistry, structural classification, and synthesis of itruvone; the pherine pharmacology and nasal chemosensory receptor mechanism; the available pharmacokinetic and tissue distribution data; preclinical pharmacology including electrophysiology and tissue distribution studies; the clinical evidence base across Phase 1 and Phase 2A trials; sourcing and quality verification for research-grade material; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative antidepressant approaches against itruvone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is an investigational drug in clinical development; investigators should obtain appropriate regulatory authorization before any human research application.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1587Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Setipiprant

Our opinion on this compoundEstablished, active research

45/100

A clean CRTH2 probe with a credible AGA repositioning angle, but the class has cooled in its primary indication

Look, setipiprant has a legitimately interesting story. The CRTH2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells, also called DP2 or GPR44) is a real target. It sits downstream of prostaglandin D2 signaling and drives the chemotaxis and degranulation of eosinophils, basophils, ILC2s, and Th2 lymphocytes. Blocking it is mechanistically sensible for type 2 inflammation, and Actelion did the chemistry properly: nanomolar potency at CRTH2, approximately 215-fold selectivity over DP1, clean COX and thromboxane profile. Thats not trivial pharmacology to nail in an orally bioavailable small molecule.

The original indications, allergic asthma and seasonal allergic rhinitis, ran through real clinical development. Phase 2 proof-of-mechanism was there. The problem is that the CRTH2 class, as a whole, got outcompeted. Biologics targeting IL-4Ra, IL-5, and TSLP moved in and captured the severe allergic disease space. Fevipiprant (AstraZeneca’s CRTH2 entry) famously failed its phase 3 asthma readout in 2019. The class didn’t vanish, but the enthusiasm in that primary indication cooled substantially. For a bench scientist, the asthma mechanistic story is well-mapped but no longer a frontier.

What keeps setipiprant worth paying attention to is the Kythera repositioning for androgenetic alopecia under the KYTH-105 designation. The Garza et al. 2012 paper in Science Translational Medicine demonstrated that PGD2 levels are significantly elevated in the balding scalp of men with male pattern hair loss and that CRTH2 is expressed on dermal papilla cells. Thats a human tissue finding, not a mouse model artifact. It opens a mechanistically distinct lane for AGA: approved therapies almost universally hit the androgen axis (finasteride, dutasteride) or are vasodilators (minoxidil). A CRTH2-mediated inflammatory mechanism would be orthogonal to all of those. Phase 2a data showed some directional signal, though effect sizes were modest and the program’s timeline has stretched without a clear phase 3 commitment.

We think the bench value here is real but bounded. If your research program touches CRTH2 biology, type 2 inflammatory pathway probing in tissue contexts, or the PGD2-hair follicle axis specifically, setipiprant is a well-characterized, selectivity-profiled tool with unusually thorough clinical-era safety data behind it. What we don’t like: the CRTH2 class has accumulated enough failed asthma trials that the surrounding investigator community has thinned, and the AGA application, while genuinely interesting, doesn’t clearly differentiate setipiprant from other CRTH2 antagonists. Honestly, this is a compound for a lab with a specific CRTH2 or inflammatory-AGA focus. For everyone else, it’s worth knowing about but not a priority acquisition.

Novelty

38

Mechanism promise

50

In-category differentiation

42

Evidence quality

48

Translational signal

42

Research bench value

50

Rationale Setipiprant scores mid-tier because the CRTH2 class delivered real clinical development but ultimately lost ground to biologics in allergic disease, and the androgenetic alopecia repositioning, while scientifically grounded in the Garza 2012 human tissue finding, produced modest phase 2a signal without clearly differentiating setipiprant from other CRTH2 antagonists. Bench value is genuine for CRTH2-focused programs but bounded by the existence of multiple class competitors.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective CRTH2 (prostaglandin D2 receptor 2/DP2) antagonist of the tetrahydropyridoindole structural class

A potent, orally bioavailable tetrahydropyridoindole antagonist of the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2/DP2), developed at Actelion as an anti-inflammatory candidate for allergic asthma and seasonal allergic rhinitis and subsequently repositioned by Kythera Biopharmaceuticals for androgenetic alopecia on the basis of the Garza et al. (2012) demonstration that prostaglandin D2 is elevated in the bald scalp of men with male pattern hair loss.

Abstract

Setipiprant (ACT-129968, KYTH-105) is a tetrahydropyridoindole derivative that acts as a potent, selective, and orally bioavailable antagonist of the chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2), also designated as the prostaglandin D2 receptor 2 (DP2 or GPR44). The compound binds the human CRTH2 receptor with an IC50 of approximately 6 nanomolar and demonstrates approximately 215-fold selectivity over the prostaglandin D2 receptor 1 (DP1), with no meaningful antagonism of the thromboxane receptor or inhibition of cyclooxygenase-1. CRTH2 is a G-protein-coupled receptor expressed on eosinophils, basophils, type 2 innate lymphoid cells, and T-helper 2 lymphocytes; activation by prostaglandin D2 drives chemotaxis, degranulation, and cytokine release from these cells, positioning CRTH2 antagonism as a mechanistically distinct anti-inflammatory strategy in allergic and type 2 inflammatory disease.

Setipiprant was discovered at Actelion Pharmaceuticals through a lead optimization program focused on improving potency and oral bioavailability within a pyrido[4,3-b]indole scaffold series. The compound advanced through Phase 1 single- and multiple-ascending-dose studies demonstrating favorable tolerability, rapid oral absorption (time to peak concentration approximately 2 to 4 hours), a terminal elimination half-life of 10 to 18 hours, and near-complete recovery of administered radioactivity in a human mass balance study (approximately 88 percent fecal, 12 percent urinary). Approximately 54 percent of administered dose was recovered as unchanged parent compound, indicating that direct fecal excretion rather than hepatic metabolism is the dominant clearance pathway. The two principal circulating metabolites, M7 and M9, are dihydroxy-dihydronaphthalene isomers formed through epoxidation of the naphthyl ring, and neither exceeds 10 percent of parent drug plasma concentrations at steady state.

Actelion advanced setipiprant through Phase 2 and Phase 3 clinical programs in seasonal allergic rhinitis and a Phase 2a proof-of-mechanism study in allergic asthma. In the allergic asthma crossover study (n=18), setipiprant at 1000 mg twice daily for 5 days significantly reduced the allergen-induced late asthmatic response by 25.6 percent (p=0.006) and protected against allergen-induced airway hyperresponsiveness to methacholine (p=0.003). In the Phase 2 seasonal allergic rhinitis trial (n=579), setipiprant 1000 mg twice daily produced statistically significant, dose-related improvement in daytime nasal symptom scores versus placebo (p=0.030), with significant improvements also observed in nighttime nasal symptoms and daytime eye symptoms. However, the Phase 3 confirmatory trial (n=630) at the same dose failed to replicate the Phase 2 efficacy signal on the primary endpoint (p=0.652), despite adequate methodology and a consistent cetirizine active-reference effect. Actelion discontinued development in the allergic rhinitis and asthma indications and redirected anti-inflammatory efforts to a follow-up CRTH2 antagonist.

The compound was subsequently repositioned for androgenetic alopecia following the Garza et al. (2012) demonstration in Science Translational Medicine that prostaglandin D2 synthase and prostaglandin D2 are elevated in the bald scalp of men with androgenetic alopecia and that prostaglandin D2 inhibits hair follicle growth through the CRTH2/GPR44 receptor. Kythera Biopharmaceuticals acquired the rights to setipiprant and submitted an Investigational New Drug application to the FDA in September 2015 (designated KYTH-105). Allergan acquired Kythera in October 2015 for approximately 2.1 billion dollars and conducted a Phase 2a randomized, double-blind, placebo-controlled trial (n=169) of setipiprant 1000 mg twice daily for 24 weeks in men with androgenetic alopecia. The trial did not meet either coprimary endpoint: target area hair count change was 6.7 hairs per square centimeter with setipiprant versus 7.0 with placebo (p=0.92), and subject self-assessment showed no difference (p=0.91). Setipiprant was well tolerated throughout all clinical programs, with headache as the most frequently reported adverse event and no severe or clinically significant safety signals identified across more than 1,500 subjects exposed in clinical trials.

This monograph reviews the chemistry, synthesis, and structural class of setipiprant; the CRTH2/DP2 receptor pharmacology and prostaglandin D2 signaling biology; the comprehensive human pharmacokinetic and metabolic disposition data; the preclinical pharmacology in inflammatory and alopecia models; the clinical evidence base across allergic rhinitis, asthma, and androgenetic alopecia; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile; and a comparative assessment of five CRTH2/DP2 receptor antagonists (fevipiprant, timapiprant, ramatroban, AZD1981, and BI-671800) against setipiprant on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation. The compound is not approved by any regulatory authority. It is available as a research-grade preparation from multiple chemical suppliers; investigators should obtain analytical confirmation of identity and purity on every lot.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1618Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026
Vatiquinone

Our opinion on this compoundNovel, promising

63/100

First-in-class 15-LO inhibitor with a real ferroptosis mechanism and Phase 3 clinical signal in rare mitochondrial disease

Vatiquinone is interesting for a specific reason: it’s not just another antioxidant dressed up as a mitochondrial compound. The NQO1-dependent bioactivation step is what separates this from CoQ10 and idebenone. The compound gets reduced intracellularly to its hydroquinone form by NAD(P)H:quinone oxidoreductase 1, and that hydroquinone then inhibits 15-lipoxygenase, the rate-limiting enzyme in ferroptotic lipid peroxidation. That’s a targeted mechanism aimed at a specific cell death program, not a generic electron-chain electron shuttle.

The ferroptosis angle matters here. Since the 2012 Dixon et al. paper naming the process, ferroptosis has become increasingly central to understanding why mitochondrially compromised neurons die. The 15-LO pathway as a proximal driver in this context is well-supported, and vatiquinone’s 1,000- to 10,000-fold potency advantage over CoQ10 in patient-derived fibroblast models isn’t marketing noise. It reflects genuine mechanistic targeting versus generic antioxidant capacity, and that delta is real.

The clinical record is more substantial than most compounds at this research stage. Edison Pharmaceuticals ran small-N but real studies in Leigh syndrome and other inherited mitochondrial diseases in the early 2010s, and the drug progressed through Phase 2 and Phase 3 (MOVE-FA) in Friedreich ataxia under PTC Therapeutics. For an orphan disease population this narrow, reaching Phase 3 with disease-modifying signals is meaningful. What we dont have is a clean approval story: omaveloxolone (Skyclarys) took the FA approval in 2023 via Nrf2 activation, and vatiquinone’s regulatory path has been complicated by small trial sizes and endpoint choices that are hard to power in ultra-rare disease.

On differentiation, vatiquinone beats CoQ10 and idebenone on mechanism specificity without question. Against omaveloxolone, the mechanisms are complementary rather than competing, which actually opens combination study interest. What we like most is the ferroptosis-specific probe value: if you want to interrogate 15-lipoxygenase’s role in neuronal death in mitochondrial disease models, vatiquinone is one of very few purpose-built tools with actual clinical-stage data behind the biology.

What we’d flag: the orphan disease focus narrows the research context considerably. Most investigators working on ferroptosis in broader neurodegeneration (ALS, Parkinson, Huntington models) haven’t anchored to vatiquinone specifically, partly because the clinical program was disease-specific and the compound isn’t widely distributed outside that context. The evidence base, while real, is small-N by design. Theres also still open questions about how broadly the anti-ferroptotic mechanism generalizes beyond primary mitochondrial disease. For investigators in mitochondrial disease, inherited ataxia, or ferroptosis biology, this is a serious compound worth tracking closely. For general neurodegeneration researchers, it’s a useful mechanistic probe that rewards closer attention than it typically gets.

Novelty

60

Mechanism promise

75

In-category differentiation

58

Evidence quality

62

Translational signal

62

Research bench value

62

Rationale Vatiquinone’s NQO1-dependent bioactivation and targeted 15-lipoxygenase inhibition genuinely distinguish it from generic quinone antioxidants; Phase 3 MOVE-FA data provide real clinical validation, but small orphan-disease N and a crowded FA approval landscape (omaveloxolone, 2023) constrain differentiation and translational scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Para-benzoquinone anti-ferroptotic agent and 15-lipoxygenase inhibitor derived from alpha-tocotrienol

A synthetic alpha-tocotrienol quinone developed by Edison Pharmaceuticals as a first-in-class 15-lipoxygenase inhibitor and anti-ferroptotic cytoprotectant for inherited mitochondrial diseases and Friedreich ataxia, distinguished from earlier quinone antioxidants by nanomolar potency in oxidative stress models, NQO1-dependent intracellular bioactivation, and disease-modifying clinical signals in pediatric neurodegeneration.

Abstract

Vatiquinone (EPI-743, PTC-743, alpha-tocotrienol quinone) is a synthetic para-benzoquinone structurally derived from the vitamin E tocotrienol family and developed as an orally bioavailable, brain-penetrant cytoprotectant for inherited mitochondrial diseases and Friedreich ataxia. The compound is the oxidized (quinone) form of alpha-tocotrienol, bearing a 2,3,5-trimethyl-1,4-benzoquinone headgroup conjugated through a hydroxylated isoprenoid side chain. Vatiquinone is reduced intracellularly by NAD(P)H:quinone oxidoreductase 1 (NQO1) to its hydroquinone form, which functions as a potent inhibitor of 15-lipoxygenase (15-LO), the rate-limiting enzyme in the ferroptotic cell death cascade that drives lipid peroxidation in mitochondrially compromised neurons and other cell types. This dual mechanism (NQO1-dependent bioactivation followed by 15-LO inhibition) distinguishes vatiquinone from earlier quinone antioxidants such as coenzyme Q10 and idebenone and underwrites a 1,000- to 10,000-fold potency advantage in patient-derived fibroblast assays modeling the oxidative stress of mitochondrial disease.

The compound was discovered at Edison Pharmaceuticals in the late 2000s, received Orphan Drug Designation from the United States Food and Drug Administration for Leigh syndrome and subsequently for Friedreich ataxia, and advanced through open-label Phase 2 studies in Leigh syndrome, Leber hereditary optic neuropathy, and other genetically defined mitochondrial disorders before the program was acquired by PTC Therapeutics in 2019. PTC Therapeutics conducted the registrational MOVE-FA Phase 3 trial (NCT04577352) in 143 patients with Friedreich ataxia aged 7 years and older. The primary endpoint of change from baseline in modified Friedreich Ataxia Rating Scale (mFARS) total score at 72 weeks did not reach statistical significance in the modified intent-to-treat population (treatment difference -1.61 points, p = 0.144). However, a prespecified sensitivity analysis of patients completing the full 72-week course demonstrated a 75 percent slowing of disease progression relative to placebo; the Upright Stability subscale of the mFARS showed a nominally significant treatment effect (-1.26 points, p = 0.021); and the Modified Fatigue Impact Scale showed a nominally significant benefit (-5.05 points, p = 0.025). In the long-term extension study, vatiquinone-treated patients progressed 3.75 points on the mFARS over 36 months compared to 7.48 points in a matched natural history cohort from the Friedreich Ataxia Clinical Outcome Measures Study registry, representing a clinically meaningful 50 percent slowing of disease progression. The FDA accepted the New Drug Application with Priority Review and set a Prescription Drug User Fee Act target date of August 19, 2025, but subsequently issued a Complete Response Letter concluding that the available data did not provide substantial evidence of efficacy and stipulating that an additional adequate and well-controlled clinical trial would be required for resubmission.

Pharmacokinetics are characterized by high lipophilicity, a pronounced food effect (medium-fat meal increases systemic exposure up to 25-fold relative to fasting), CYP3A4-mediated hepatic metabolism, high plasma protein binding (greater than 96 percent), an effective half-life of approximately 9 hours supporting three-times-daily dosing with meals, and predominantly fecal elimination. The compound is generally well tolerated; the principal adverse events in clinical trials have been mild gastrointestinal symptoms and elevations in plasma cholesterol. This monograph reviews the chemistry, synthesis, and structural pharmacology of vatiquinone; the NQO1-mediated bioactivation and 15-lipoxygenase inhibition mechanism; the comprehensive pharmacokinetic record including drug-drug interaction characterization; the preclinical evidence across ferroptosis, mitochondrial disease, and Friedreich ataxia models; the clinical evidence base from Leigh syndrome through MOVE-FA; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative compounds (omaveloxolone, idebenone, coenzyme Q10, elamipretide, nicotinamide riboside) against vatiquinone on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1605Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 20, 2026

←Previous Page

1 … 7 8 9 10 11 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.